Pancreatic Cancer Research

ResearcherSapporo Medical UniversityActive in the last 2 years

Tsuyoshi Hayashi

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-7666-5795; OpenAlex author ID A5058075352. Sources: OpenAlex.

Their work

Papers
10 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
50
Papers, trials and grants by year

2012: 1 paper · 2013: none · 2014: none · 2015: 2 papers · 2016: none · 2017: none · 2018: none · 2019: 2 papers · 2020: 1 paper · 2021: none · 2022: 1 paper · 2023: 2 papers · 2024: none · 2025: none · 2026: 1 paper

Papers 10

  1. Early Detection of Pancreatic Adenocarcinoma Using Triple-phase contrast-enhanced Computed Tomography: A Case-control Study. Co-author DOI 10.1097/mpa.0000000000002712↗
  2. Impact of S-1 adjuvant chemotherapy longer than 6 months on survival in patients with resected pancreatic cancer: a nationwide survey by the Japan Pancreas Soc… Co-author DOI 10.1002/cncr.34580↗
  3. Standard versus delayed initiation of S-1 adjuvant chemotherapy after surgery for pancreatic cancer: a secondary analysis of a nationwide cohort by the Japan P… Co-author DOI 10.1007/s00535-023-01988-7↗
  4. HOPS-R01 phase II trial evaluating neoadjuvant S-1 therapy for resectable pancreatic adenocarcinoma. First author DOI 10.1038/s41598-022-14094-0↗
  5. Clinical Outcomes of Biliary Drainage during a Neoadjuvant Therapy for Pancreatic Cancer: Metal versus Plastic Stents. Co-author DOI 10.5009/gnl18573↗
  6. Clinical usefulness of conversion surgery for unresectable pancreatic cancer diagnosed on multidetector computed tomography imaging: Results from a multicenter… Co-author DOI 10.1002/ags3.12272↗
  7. Phase 2 Study of Neoadjuvant Treatment of Sequential S-1-Based Concurrent Chemoradiation Therapy Followed by Systemic Chemotherapy with Gemcitabine for Borderl… Co-author DOI 10.1016/j.ijrobp.2019.07.004↗
  8. No benefit of endoscopic sphincterotomy before biliary placement of self-expandable metal stents for unresectable pancreatic cancer. Co-author DOI 10.1016/j.cgh.2015.01.008↗
  9. A case of curatively resected gastric wall implantation of pancreatic cancer caused by endoscopic ultrasound-guided fine-needle aspiration. First author DOI 10.1055/s-0034-1377592↗
  10. Targeting anticancer drug delivery to pancreatic cancer cells using a fucose-bound nanoparticle approach. Co-author DOI 10.1371/journal.pone.0039545↗

Closest collaborators

The 25 strongest of 50 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yasutoshi Kimura · 6 shared papers, 2015–2023 · strength 0.55
  2. Hajime Yamazaki · 2 shared papers, 2019–2026 · strength 0.36
  3. Akio Katanuma · 2 shared papers, 2019–2026 · strength 0.36
  4. Satoshi Hirano · 4 shared papers, 2019–2022 · strength 0.35
  5. Masayo Motoya · 4 shared papers, 2019–2022 · strength 0.35
  6. Yasuo Sakurai · 1 shared paper, 2026 · strength 0.29
  7. Sohei Satoi · 2 shared papers, 2023 · strength 0.27
  8. Hidetoshi Eguchi · 2 shared papers, 2023 · strength 0.27
  9. Yoshito Tomimaru · 2 shared papers, 2023 · strength 0.27
  10. Shoji Kawakatsu · 2 shared papers, 2023 · strength 0.27
  11. Yoshifumi Takeyama · 2 shared papers, 2023 · strength 0.27
  12. Akihiro Ohba · 2 shared papers, 2023 · strength 0.27
  13. Yuichi Nagakawa · 2 shared papers, 2023 · strength 0.27
  14. Michiaki Unno · 2 shared papers, 2023 · strength 0.27
  15. Toru Nakamura · 3 shared papers, 2019–2020 · strength 0.26
  16. Hirotoshi Ishiwatari · 3 shared papers, 2015–2022 · strength 0.20
  17. Masaki Kuwatani · 2 shared papers, 2019–2020 · strength 0.18
  18. Masafumi Imamura · 2 shared papers, 2019–2022 · strength 0.18
  19. Makoto Yoshida · 2 shared papers, 2019 · strength 0.15
  20. Shunsuke Onoe · 1 shared paper, 2023 · strength 0.14
  21. Daisuke Hashimoto · 1 shared paper, 2023 · strength 0.14
  22. Yosuke Inoue · 1 shared paper, 2023 · strength 0.14
  23. Kenichiro Uemura · 1 shared paper, 2023 · strength 0.14
  24. Tamotsu Kuroki · 1 shared paper, 2023 · strength 0.13
  25. Hisato Igarashi · 1 shared paper, 2023 · strength 0.13

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.